It has not normally been OHE policy to reprint articles which have previously been published elsewhere. However, it seemed desirable to make an exception for this paper by Dr Klaus von Grebmer which has been published in two parts in German in Die Pharmazeutische Industrie. This is because it is a useful compilation of many arguments relating to pharmaceutical pricing, which deserves to be available in the English language as well as in German.

It is also useful for British readers to be able to view some of the current problems of pharmaceutical pricing ‘through European eyes’, as it were. For these reasons OHE is grateful to Dr von Grebmer and to the Editor of Die Pharmazeutische Industrie for permission to publish this booklet. The responsibility for the views expressed, however, must remain that of Klaus von Grebmer rather than OHE.